This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as well as the possible impacts of these factors on the outcome of progression, exacerbations, and mortality in patients with ILD associated to CTD.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Time to first exacerbation: time in months elapsed until the first exacerbation from the diagnosis
Timeframe: up to 13 years
Number of exacerbation per year (frequency of exacerbation)
Timeframe: up to 13 years
Percent of pulmonary fibrosis: grade of parenchymal involvement evidenced by high-resolution computed tomography (HRCT)
Timeframe: up to 13 years
Change in 6-minute walk tests (6-MWT) over time
Timeframe: up to 13 years
King's Brief Interstitial Lung Disease Questionnaire (K-BILD) score change over time
Timeframe: up to 13 years
Saint George Respiratory Questionnaire (SGRQ)-I score change over time
Timeframe: up to 13 years